Project/Area Number |
26461206
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Respiratory organ internal medicine
|
Research Institution | National Cancer Center Japan |
Principal Investigator |
Fujiwara Yutaka 国立研究開発法人国立がん研究センター, 中央病院, 医長 (70464261)
|
Research Collaborator |
Asao Tetsuhiko
Kohno Takashi
Ichikawa Hitoshi
Saito Motonobu
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2015: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2014: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
|
Keywords | 胸腺癌 / 化学療法 / 遺伝子Profile / 次世代シークエンサー / thymic carcinoma / TET2 / DNA methylation / 胸腺がん / がん遺伝子 / 遺伝子増幅 / 遺伝子変異 / 遺伝子癒合 / 遺伝子融合 |
Outline of Final Research Achievements |
The aim of this study is to investigate the genomic and epigenomic alterations by next generation sequencing of thymic cancer as target for anti-cancer therapy. Sixty-four consecutive patients with thymic carcinoma treatedat the National Cancer Hospital between 1973 and 2014 were included in this study. Tissue samples of 52 patients (81.3%) were available for targeted sequencing of mutation hot spots in 50cancer-related genes by IonAmpliseq Cancer Hotspot Panel v2. The genetic alterations of TP53, KRAS, FBXW7, and NRAS were detected in 7 patients (13.5%). In whole exome and transcriptome sequencing from paired snap-frozen cancerous or non-cancerous tissues (n=10), we identified a mutation signature consisting of enrichment for C>T substitutions at CpG dinucleotides. And we also identifies thymic cancers with TET2 mutations had more hypermethylated genes than those without, and hyper-methylation was associated with downregulation of gene expression.
|